bromhexine has been researched along with Hyaline Membrane Disease in 3 studies
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).
Hyaline Membrane Disease: A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective double-blind clinical trial was carried out to determine whether ambroxol (bromhexine metabolite VIII) treatment (1000 mg/day for a period of 5 days) reduces the risk of hyaline membrane disease (HMD) in potentially premature infants." | 9.05 | The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study. ( Böttcher, M; Fricke, U; Grauel, EL; Hinkel, GK; Jacobi, R; Koepke, E; Köppe, I; Kunze, D; Lachmann, B; Lampe, K; Menzel, K; Methfessel, G; Müller, K; Nitz, I; Plath, C; Reichmann, G; Schlegel, C; Schmalisch, G; Schmidt, W; Schröder, M; Severin, K; Sitka, U; Tiller, R; Wauer, RR, 1982) |
| "To estimate the efficacy of ambroxol for clinical use in prenatal prevention and postnatal therapy of hyaline membrane disease (HMD) all available experimental and clinical data were reviewed." | 8.77 | Ambroxol for prevention and treatment of hyaline membrane disease. ( Buttenberg, S; Hammer, H; Huth, M; Schmalisch, G; Wauer, RR; Weigel, H, 1989) |
| "A prospective double-blind clinical trial was carried out to determine whether ambroxol (bromhexine metabolite VIII) treatment (1000 mg/day for a period of 5 days) reduces the risk of hyaline membrane disease (HMD) in potentially premature infants." | 5.05 | The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study. ( Böttcher, M; Fricke, U; Grauel, EL; Hinkel, GK; Jacobi, R; Koepke, E; Köppe, I; Kunze, D; Lachmann, B; Lampe, K; Menzel, K; Methfessel, G; Müller, K; Nitz, I; Plath, C; Reichmann, G; Schlegel, C; Schmalisch, G; Schmidt, W; Schröder, M; Severin, K; Sitka, U; Tiller, R; Wauer, RR, 1982) |
| "To estimate the efficacy of ambroxol for clinical use in prenatal prevention and postnatal therapy of hyaline membrane disease (HMD) all available experimental and clinical data were reviewed." | 4.77 | Ambroxol for prevention and treatment of hyaline membrane disease. ( Buttenberg, S; Hammer, H; Huth, M; Schmalisch, G; Wauer, RR; Weigel, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wauer, RR | 2 |
| Schmalisch, G | 2 |
| Menzel, K | 1 |
| Schröder, M | 1 |
| Müller, K | 1 |
| Tiller, R | 1 |
| Methfessel, G | 1 |
| Sitka, U | 1 |
| Koepke, E | 1 |
| Plath, C | 1 |
| Schlegel, C | 1 |
| Böttcher, M | 1 |
| Köppe, I | 1 |
| Fricke, U | 1 |
| Severin, K | 1 |
| Jacobi, R | 1 |
| Schmidt, W | 1 |
| Hinkel, GK | 1 |
| Nitz, I | 1 |
| Kunze, D | 1 |
| Reichmann, G | 1 |
| Lachmann, B | 1 |
| Lampe, K | 1 |
| Grauel, EL | 1 |
| Saule, H | 1 |
| Hammer, H | 1 |
| Buttenberg, S | 1 |
| Weigel, H | 1 |
| Huth, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for bromhexine and Hyaline Membrane Disease
| Article | Year |
|---|---|
[Anti-atelectasis factor (surfactant) and hyaline membrane disease in premature infants].
Topics: Adrenal Cortex Hormones; Animals; Bromhexine; Female; Gestational Age; Hot Temperature; Humans; Hyal | 1975 |
Ambroxol for prevention and treatment of hyaline membrane disease.
Topics: Adrenal Cortex Hormones; Ambroxol; Animals; Bromhexine; Guinea Pigs; Humans; Hyaline Membrane Diseas | 1989 |
Ambroxol for prevention and treatment of hyaline membrane disease.
Topics: Adrenal Cortex Hormones; Ambroxol; Animals; Bromhexine; Guinea Pigs; Humans; Hyaline Membrane Diseas | 1989 |
Ambroxol for prevention and treatment of hyaline membrane disease.
Topics: Adrenal Cortex Hormones; Ambroxol; Animals; Bromhexine; Guinea Pigs; Humans; Hyaline Membrane Diseas | 1989 |
Ambroxol for prevention and treatment of hyaline membrane disease.
Topics: Adrenal Cortex Hormones; Ambroxol; Animals; Bromhexine; Guinea Pigs; Humans; Hyaline Membrane Diseas | 1989 |
1 trial available for bromhexine and Hyaline Membrane Disease
| Article | Year |
|---|---|
The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study.
Topics: Ambroxol; Amniotic Fluid; Bromhexine; Clinical Trials as Topic; Double-Blind Method; Female; Gestati | 1982 |